Celebrating an incredible milestone: WOMAN-2 trial achieves target of 15,000 randomised women
Well done to WOMAN-2 sites for over 14,000 women randomised.
Severe anaemia linked to seven-fold increased risk of death or life-threatening bleeding after childbirth.
WHO Postpartum Haemorrhage (PPH) Roadmap.
Lifesaving drug for severe bleeding after childbirth could be made accessible for all.
A call for global action on International Women’s Day to address the leading cause of maternal death worldwide.
End of year update
Congratulations on the most successful year for the WOMAN-2 Trial.
Congratulations to our WOMAN-2 Trial global team.
Thank you for an amazing year – 6620 women randomised.
On our way to finding better ways to treat women.
Hospitals have restarted the trial, after recruitment stopped due to COVID-19.